(ALC) Alcon - Ratings and Ratios
Surgical Equipment, IOLs, Contact Lenses, Dry Eye Drops, Vitreoretinal Tools
ALC EPS (Earnings per Share)
ALC Revenue
Description: ALC Alcon
Alcon Inc. (NYSE: ALC) is a global eye-care company headquartered in Geneva, Switzerland, operating through two primary segments: Surgical and Vision Care. The Surgical segment delivers a full suite of intra-ocular lenses (IOLs), implantable devices, and consumables for cataract and vitreoretinal procedures, while Vision Care focuses on contact lenses, ocular-health products, and over-the-counter eye-care items.
In the Surgical arena, Alcon’s portfolio includes the Centurion and LenSx laser systems, the Verion digital marker, the ARGOS biometer, and the NGENUITY 3-D visualization platform, alongside a range of monofocal, toric, and presbyopia-correcting IOLs delivered via AutonoMe and UltraSert injection systems. The company also supplies vitreoretinal solutions such as the Constellation vision system, MIVS instruments, and Hypervit vitrectomy probes, as well as refractive-surgery lasers (WaveLight) and the Contoura Vision platform for LASIK.
Alcon’s Vision Care segment offers daily disposable, reusable, and color-enhancing contact lenses, plus ocular-health products covering dry eye, allergies, glaucoma, lens care solutions, ocular vitamins, and redness relievers. This breadth allows cross-selling opportunities between surgical patients and long-term contact-lens users.
Key performance indicators from the most recent fiscal year show total revenue of approximately $8.5 billion, with the Surgical segment contributing roughly 55 % and growing at a 4 % CAGR over the past three years, driven by an aging global population and rising cataract surgery rates. The Vision Care segment posted a 6 % YoY increase in contact-lens sales, supported by premium-lens pricing power and expanding emerging-market penetration. Macro-level drivers include favorable Medicare reimbursement trends for cataract procedures and ongoing demand for refractive-surgery solutions as consumer preference for spectacle-free vision rises.
For a deeper, data-driven assessment of Alcon’s valuation and risk profile, you may find it useful to explore the analytics available on ValueRay.
ALC Stock Overview
| Market Cap in USD | 36,855m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-04-09 |
ALC Stock Ratings
| Growth Rating | 11.6% |
| Fundamental | 58.0% |
| Dividend Rating | 53.1% |
| Return 12m vs S&P 500 | -31.1% |
| Analyst Rating | 4.33 of 5 |
ALC Dividends
| Dividend Yield 12m | 0.44% |
| Yield on Cost 5y | 0.55% |
| Annual Growth 5y | 7.93% |
| Payout Consistency | 99.5% |
| Payout Ratio | 11.6% |
ALC Growth Ratios
| Growth Correlation 3m | -94.1% |
| Growth Correlation 12m | -44.6% |
| Growth Correlation 5y | 67.8% |
| CAGR 5y | 9.23% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.33 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.13 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -33.38 |
| Beta | 0.693 |
| Volatility | 29.62% |
| Current Volume | 2875.2k |
| Average Volume 20d | 2380.8k |
| Stop Loss | 73.1 (-3.1%) |
| Signal | -0.30 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.07b TTM) > 0 and > 6% of Revenue (6% = 601.5m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 1.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 38.72% (prev 37.85%; Δ 0.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 2.06b > Net Income 1.07b (YES >=105%, WARN >=100%) |
| Net Debt (3.84b) to EBITDA (1.73b) ratio: 2.22 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (497.9m) change vs 12m ago 0.18% (target <= -2.0% for YES) |
| Gross Margin 55.13% (prev 55.37%; Δ -0.23pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.81% (prev 32.42%; Δ 0.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.79 (EBITDA TTM 1.73b / Interest Expense TTM 197.8m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 57.95
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.93% = 1.96 |
| 3. FCF Margin 15.94% = 3.99 |
| 4. Debt/Equity 0.24 = 2.47 |
| 5. Debt/Ebitda 2.22 = -0.43 |
| 6. ROIC - WACC (= -5.11)% = -6.39 |
| 7. RoE 4.93% = 0.41 |
| 8. Rev. Trend 88.85% = 6.66 |
| 9. EPS Trend -24.35% = -1.22 |
What is the price of ALC shares?
Over the past week, the price has changed by +3.94%, over one month by -2.73%, over three months by -13.42% and over the past year by -19.73%.
Is Alcon a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALC is around 65.63 USD . This means that ALC is currently overvalued and has a potential downside of -13.03%.
Is ALC a buy, sell or hold?
- Strong Buy: 15
- Buy: 6
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.1 | 27.4% |
| Analysts Target Price | 96.1 | 27.4% |
| ValueRay Target Price | 72.6 | -3.8% |
Last update: 2025-10-17 03:45
ALC Fundamental Data Overview
P/E Trailing = 34.2546
P/E Forward = 20.9644
P/S = 3.6763
P/B = 1.6792
P/EG = 1.7635
Beta = 0.693
Revenue TTM = 10.03b USD
EBIT TTM = 749.7m USD
EBITDA TTM = 1.73b USD
Long Term Debt = 4.66b USD (from longTermDebt, last quarter)
Short Term Debt = 147.0m USD (from shortTermDebt, last quarter)
Debt = 5.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.84b USD (from netDebt column, last quarter)
Enterprise Value = 40.70b USD (36.85b + Debt 5.25b - CCE 1.41b)
Interest Coverage Ratio = 3.79 (Ebit TTM 749.7m / Interest Expense TTM 197.8m)
FCF Yield = 3.93% (FCF TTM 1.60b / Enterprise Value 40.70b)
FCF Margin = 15.94% (FCF TTM 1.60b / Revenue TTM 10.03b)
Net Margin = 10.70% (Net Income TTM 1.07b / Revenue TTM 10.03b)
Gross Margin = 55.13% ((Revenue TTM 10.03b - Cost of Revenue TTM 4.50b) / Revenue TTM)
Gross Margin QoQ = 53.47% (prev 55.92%)
Tobins Q-Ratio = 1.30 (Enterprise Value 40.70b / Total Assets 31.39b)
Interest Expense / Debt = 0.97% (Interest Expense 51.0m / Debt 5.25b)
Taxrate = 11.56% (23.0m / 199.0m)
NOPAT = 663.0m (EBIT 749.7m * (1 - 11.56%))
Current Ratio = 2.60 (Total Current Assets 6.31b / Total Current Liabilities 2.42b)
Debt / Equity = 0.24 (Debt 5.25b / totalStockholderEquity, last quarter 22.11b)
Debt / EBITDA = 2.22 (Net Debt 3.84b / EBITDA 1.73b)
Debt / FCF = 2.40 (Net Debt 3.84b / FCF TTM 1.60b)
Total Stockholder Equity = 21.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.42% (Net Income 1.07b / Total Assets 31.39b)
RoE = 4.93% (Net Income TTM 1.07b / Total Stockholder Equity 21.76b)
RoCE = 2.84% (EBIT 749.7m / Capital Employed (Equity 21.76b + L.T.Debt 4.66b))
RoIC = 2.49% (NOPAT 663.0m / Invested Capital 26.58b)
WACC = 7.61% (E(36.85b)/V(42.11b) * Re(8.57%) + D(5.25b)/V(42.11b) * Rd(0.97%) * (1-Tc(0.12)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.48%
[DCF Debug] Terminal Value 79.75% ; FCFE base≈1.39b ; Y1≈1.72b ; Y5≈2.93b
Fair Price DCF = 91.06 (DCF Value 45.02b / Shares Outstanding 494.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -24.35 | EPS CAGR: -50.83% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.85 | Revenue CAGR: 7.28% | SUE: -1.24 | # QB: 0
Additional Sources for ALC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle